Olink

Olink®
Part of Thermo Fisher Scientific

Distinct plasma proteomic trajectories during PD-1 blockade and PEG-IFNα therapy are associated with HBsAg response in chronic hepatitis B

Frontiers in Cellular and Infection Microbiology, 2026

Wang H., Li Y., Li X., Zhang X., Wang Q., Liu S., Yang S., Zhang X., Qiao X., Dang S., Wang F., Fu J.

Disease areaApplication areaSample typeProducts
Infectious Diseases
Immunotherapy
Pathophysiology
Plasma
Olink Target 96

Olink Target 96

Abstract

Background

PD-1 blockade and pegylated interferon-α (PEG-IFNα) are promising immunomodulatory strategies for chronic hepatitis B (CHB), but their systemic immune effects and response-associated proteomic patterns remain poorly defined.

Methods

We performed longitudinal plasma proteomic profiling using the Olink Target 96 Inflammation panel in 25 nucleos(t)ide analogue-suppressed patients with CHB receiving PD-1 blockade (n=10) or PEG-IFNα (n=15). Plasma samples were collected at baseline, week 12, and week 24. Longitudinal protein changes were analyzed using linear mixed-effects models, and associations with week-24 HBsAg decline were evaluated using responder–non-responder comparisons and Spearman’s rank correlation. Responders were defined by an HBsAg decline of ≥1 log 10 IU/mL at week 24.

Results

Seventy-seven proteins passed quality-control criteria. PEG-IFNα induced substantially broader longitudinal proteomic remodeling than PD-1 blockade, with most changes occurring within the first 12 weeks. Treatment-by-time analyses identified distinct trajectories between therapies, including differential changes in IL-18R1, TNF, CX3CL1, CXCL9, and CXCL10. Response-associated analyses suggested treatment-specific patterns: IL-10 was the leading exploratory signal in the PD-1 cohort, whereas IL-12B, CDCP1, and FGF-21 were more prominent in the PEG-IFNα cohort. These response-related associations did not remain significant after false discovery rate correction and were therefore considered exploratory.

Conclusions

PD-1 blockade and PEG-IFNα induce distinct longitudinal circulating inflammatory proteomic programs in CHB. Favorable HBsAg decline was accompanied by treatment-specific rather than universal proteomic signatures, supporting the potential value of longitudinal proteomics for mechanistic and biomarker studies of HBV functional-cure strategies.

Read publication ↗